Most pages either dismiss oral BPC-157 entirely ("peptides are destroyed in the gut") or wave the issue away ("it's gastric in origin so it survives")
503B Distinction The FDA's 2024 decision removed BPC-157 from 503B outsourcing facility eligibility
For the maintenance treatment of vitamin B12 deficiency, the usual dose is 60-100mcg SC/IM, given once per month
Patients who should wait before starting BPC-157: those with active malignancy or a personal history of hormone-sensitive cancer, pregnant patients, and anyone who has not yet completed a basic anti-inflammatory protocol for an acute injury
Possible signs include jawline prominence, enlarged hands/feet, coarse facial features, and organ enlargement (rare and associated with long-term abuse)
Independent testing services are seeing increased demand